Immunization with recombinant gp160 prolongs the survival of HIV-1 transgenic mice.
A strain of mouse transgenic for the env gene of the HIV-1 virus was used to study the immunogenicity of a gp160-derived vaccine (the protein encoded by the HIV env gene) and its effect on disease progression. Untreated transgenic mice frequently developed a rapidly progressive renal disease similar to that affecting approximately 10% of HIV-infected humans. When transgenic mice were immunized with recombinant purified gp160, their edema, proteinuria, and serum BUN levels were substantially reduced and their survival prolonged (p < 0.01). The increased longevity of immunized transgenic mice correlated with the production of IgG antibodies reactive with gp160.
Shirai
A
A
Section of Retroviral Immunology, Food and Drug Administration, Bethesda, MD 20892.
Klinman
D M
DM
D016915:AIDS Vaccines / Q000627:therapeutic use*; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000818:Animals; D015153:Blotting, Western; D004797:Enzyme-Linked Immunosorbent Assay; D015686:Gene Products, env / Q000276:immunology*; D015483:HIV Antibodies / Q000097:blood; D019302:HIV Envelope Protein gp160; D015497:HIV-1 / Q000235:genetics; D007114:Immunization; D051379:Mice; D008822:Mice, Transgenic; D009404:Nephrotic Syndrome / Q000517:prevention & control*; D011498:Protein Precursors / Q000276:immunology*; D011533:Proviruses / Q000235:genetics; D016019:Survival Analysis; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
D016915:AIDS Vaccines; D015686:Gene Products, env; D015483:HIV Antibodies; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; D014614:Vaccines, Synthetic